Sign In
|
Register
|
About San Anselmo
|
Contact Us
San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast
|
Traffic
San Anselmo News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
San Anselmo Gas Prices
Ski And Snow Reports
Financial Markets
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Attractions
Antiques
Nightlife
Family Activities
Arts & Culture
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Apartment Finding & Rentals
Apartments
Senior Apartments
Art & Culture
Galleries & Dealers
Museums
Theatres
Associations, Foundations and Organizations
Business & Professional Clubs
Chambers of Commerce
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Sales Organizations
Attractions & Entertainment
Amusement & Water Parks
Galleries
General Attractions
Museums
Parks & Preserves
Theatre
Automotive
Dealers - Antique & Classic
Dealers - New
Dealers - Used
Motorcycles
Parts & Supplies
Repair & Service
Beauty & Fitness
Barbers
Beauty Salons
Dance Clubs & Studios
Fitness Programs
Health Clubs & Gyms
Massage
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business Legal Services
Communications Services
Computer & Audio Visual Services
Consultants
Copier & Fax Services, Equipment
Data Processing Service
Durable Goods
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Management Services
Marketing & Advertising Services
Media Services
Office Furniture, Equipment & Supplies
Photography
Printing & Publishing
Public Relations & Publicity
Research
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Telecommunications
Trucking & Hauling
Video Production
Commercial Contractors
Concierge & Lifestyle Services
Contractors
Architects
Building Contractors & Consultants
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Pet Sitting and Day Care
Education
Art Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Middle Schools
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Appraisers
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Misc. Financial Services
Mortgage Lenders
Personal
Government
Post Offices
Health and Medicine
Alternative Medicine / Acupuncture
Animal Health
Chiropractors
Counseling
Dentistry
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Massage
Medical Doctors
Mental Health
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Accessories
Bed & Bath
Cabinets, Racks & Shelves
Carpets & Rugs
Cleaning Supplies & Services
Contractors
Electric
Floor Coverings
Furniture
Heating, Cooling & AC
Home Improvement Centers
Kitchen
Lamps & Lighting
Lawn & Garden
Masonry & Stone Work
Nurseries & Garden Centers
Painting & Wallcoverings
Plumbing
Tree Services
Insurance
Agents & Brokers
Auto
Health
Home
Life
Pets
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Food & Beverage
Media
Cable & Pay TV Services
Print Publications
Television Stations
Meeting & Event Planning
Audio & Visual
Event Facilities
Exhibit Designers
Lodging
Meeting Planners
Party Rentals & Entertainment
Travel Arrangement & Services
Miscellaneous
Nightlife
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Personal Service
Barbers, Beauty Salons & Spas
Shoe Repair
Pets
Pet Shops
Training
Veterinary Hospitals
Real Estate
Appraisers
Commercial
Condominiums
Developers
Mortgage Lenders
Property Management
Real Estate Agents and Brokers
Residential
Religion
Relocation
Movers
Storage
Restaurants
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Shopping
Accessories
Antiques
Books
Bridal Shops
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Convenience Stores
Department Stores
Discount Stores
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Gourmet & Specialty Foods
Grocery Stores
Health Food Stores
Home Improvement
Indian Arts & Crafts - Retail
Jewelry
Men's Clothing Stores
Notions
Office Supplies & Service
Pharmacies
Repair Shops
Resale Shops
Shoe Stores
Sporting Goods
Thrift Stores
Videos
Women's Clothing Stores
Spas
Beauty Salons
Sports & Recreation
Bicycles
Dance Clubs & Studios, Instruction
Health Clubs
Instruction
Recreation Facilities
Sporting Goods
Technology
Communications
Computer Maintenance and Repair
Computer Services & Consultants
E-commerce
Internet Advertising & Services
Semiconductor
Software
Web Design
Web Development
Travel & Transportation
Hotels & Resorts
Taxi, Limousine & Shuttle
Travel Agencies
Weddings
Bridal Shops
Entertainment
Florists
Health & Beauty
Photographers & Videographers
Apartments
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in San Anselmo
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innovent Biologics Inc
(OP:
IVBXF
)
5.210
UNCHANGED
Streaming Delayed Price
Updated: 12:34 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Innovent Biologics Inc
< Previous
1
2
Next >
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
March 09, 2024
Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale...
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
August 04, 2022
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...
Via
Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....
Via
Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
November 04, 2023
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...
Via
Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
August 26, 2023
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may...
Via
Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023
Via
Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates...
Via
Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
June 10, 2023
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...
Via
Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...
Via
Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
February 04, 2023
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...
Via
Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...
Via
Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
December 10, 2022
In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and...
Via
Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
March 24, 2022
The
Via
Benzinga
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
February 11, 2022
The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was...
Via
Benzinga
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
September 28, 2021
Privately-held UNION therapeutics A/S and Innovent Biologics Inc's (OTC: IVBIY) subsidiary have entered into a strategic collaboration and license...
Via
Benzinga
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
August 27, 2021
Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The...
Via
Benzinga
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
August 16, 2021
Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall...
Via
Benzinga
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
August 06, 2021
Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly And Co (NYSE: LLY) have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab...
Via
Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
July 09, 2021
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking...
Via
Benzinga
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
June 03, 2021
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY)...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
San Anselmo
|
San Anselmo News
|
San Anselmo Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Calendar
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.